Sun Pharma Advanced Research Co. Ltd. · NSE:SPARC
Sun Pharma Advanced Research — JP Morgan 42nd Annual Healthcare Conference (January 2024)
25 slides from Sun Pharma Advanced Research's conference presentation, January 2024
Slide 1: JP Morgan 42nd Annual Healthcare Conference
JP Morgan 42nd Annual Healthcare Conference Anil Raghavan Chief Executive Officer January 2024 BSE:532872 NSE: SPARC BLOOMBERG: SPADV@IN REUTERS: SPRC.BO CIN:L73100GJ2006PLC047837
Slide 2: Forward-looking statements
Forward-looking statements This presentation and its contents should not be distributed, published or reproduced, in whole or part, or disclosed by recipients directly or indirectly to any other person. Any failure to comply with these restrictions may constitute a violation of applicable laws. Acco
Slide 3: Capital efficient translational engine
Capital efficient translational engine Maturing operating model with global access to science Unique origins Strategic pivot Operating model advantage First listed R&D company out of India Shift from 505(b)(2) assets Captive capability – Bench to bedside Founders still own 70% and continue 3 NCEs in
Slide 4: Value drivers of the portfolio
Value drivers of the portfolio Led by a potentially transformational program in neurodegenerative diseases Vodobatinib Optionality A selective, brain penetrant c-Abl kinase Vodobatinib’s clinical Vibozilimod, a third inhibitor moderating oxidative stress 1 PoC established in Chronic 2 generation, S1
Slide 5: Approaching important data events
Approaching important data events 2024 offers multiple clinical proof-of-concept readouts Asset/Program MoA Indication Discovery Preclinical Phase 1 Phase 2 Upcoming Catalysts Parkinson’s Interim analysis result in Q2 2024 Disease Phase 2 data readout in Q3 2024 Vodobatinib c-ABL Lewy Body Phase 2 d
Slide 6: Vodobatinib targets a disease driver
Vodobatinib targets a disease driver Low promiscuity, Robust brain levels Role of c-Abl in Parkinson’s Disease c-Abl – Key driver of neurodegeneration cascade c-Abl is activated in oxidative stress response Triggers toxic degenerative cascade through key substrates Crucial role in protein aggregatio
Slide 7: Neuroprotection in classic PD models
Neuroprotection in classic PD models Consistent validation in collaboration with global thought leaders PFF-induced mouse model 1 AAV mutant α-Synuclein (hA53T) rat model 2 20 NS ** ** * NS p=>0.0043 p=>0.9999 p=0.0111 15 1.0 L L R L L Specific Striatal 125IRTI-121 p=>0.9999 Turning time (sec) 0.8 R
Slide 8: Early clinical studies support translation
Early clinical studies support translation Vodobatinib confirmed target coverage in CSF at safe doses Phase 1 completed in healthy subjects and PD subjects with doses up to 384mg per day Overall well tolerated CSF PK suggests adequate brain penetration over 24 hours 192mg and 384mg doses proposed fo
Slide 9: PROSEEK aims a reproducible PoC
PROSEEK aims a reproducible PoC In L-Dopa naïve, DaT confirmed early PD patients PROSEEK study design Primary endpoint Change in MDS-UPDRS Part 3 Screening Key secondary endpoints Change in MDS-UPDRS Part 2+Part 3 Randomization Time to the start of symptomatic medication Clinician global impression
Slide 10: PROSEEK achieved enrolment target
PROSEEK achieved enrolment target Completed enrolment in October 2023 PROSEEK – Global patient distribution Over 40% patients enrolled from the US 221 89 Drug related SAEs reported in 1.2% patients 85 No significant cardiac events reported 80 GI and rash were the most common AEs reported 21 No chang
Slide 11: c-Abl inhibition promises broad impact
c-Abl inhibition promises broad impact Reduces toxic proteins implicated in multiple diseases 21 days iPSC-Neurons Analysis of cell lysate and culture supernatant Vodobatinib DMSO 10 nM Vodobatinib 10 nM 150 p- cAbl (Tyr 412) 150 Tot cAbl ELISA detection of Aẞ40 and Aẞ42 in culture supernatant Aẞ40
Slide 12: PROSEEK validates a key mechanism
PROSEEK validates a key mechanism Vodobatinib as a backbone to SoC across the continuum of care PRE-DIAGNOSIS PARKINSON'S DISEASE DIAGNOSIS Vodobatinib’s Sensory symptoms EARLY STAGES PROSEEK target ADVANCED STAGES Vodobatinib future Treatment opportunity spectrum and non-specific pain population de
Slide 13: Vibozilimod: best-in-class S1PR1 agonist
Vibozilimod: best-in-class S1PR1 agonist Safe oral alternative to JAK inhibitors in derma autoimmune disorders S1P functional activity using GTPγS assay EC50 GTPγs (nM) S1PR1 agonists S1PR1 S1PR3 S1PR5 Vibozilimod Fingolimod 0.2 0.4 >10,000 7.7 9 2.2 Potential to lead the Ozanimod 1.9 >10,000 3.5 S1
Slide 14: PK-PD validation from early clinical studies
PK-PD validation from early clinical studies Therapeutically relevant lymphopenia at safe doses Heart rate & lymphocyte reduction following Multiple Doses 100 HR Decrease (bmp)/ALC drop;% 80 81 80 75 68 70 66 68 63 60 55 Max drop in Mean HR (bpm) 51 Trough Lymphopenia% 40 Nadir Lymphopenia% 20 0 -5.
Slide 15: Vibozilimod clinical PoC studies ongoing
Vibozilimod clinical PoC studies ongoing Therapeutically relevant lymphopenia at safe doses A randomized, double-blind, placebo-controlled study to A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Vibozilimod in the treatment of assess the efficacy and safety
Slide 16: Vibozilimod clinical PoC studies ongoing
Vibozilimod clinical PoC studies ongoing Program poised for significant data events in 2024 Recruitment Primary AD Phase 3 completion expected endpoint topline initiation in Q1, in Q2, 2024 in Q4, 2024 2025 Vibozilimod is partnered with Sun Pharma with ~50% economics retained with SPARC SPARC © 2024
Slide 17: SCD-153 targeting novel pathway in AA
SCD-153 targeting novel pathway in AA Built on an endogenous immunosuppressive metabolite SCD-153 blocks key inflammatory cytokines implicated in AA Healthy Alopecia Areata MHC Class I & Class II CD4+ T cell Outer root sheath CD8+ T cell Sebaceous gland Hair shaft Antigen Presenting cells Bulb Immun
Slide 18: Promising preclinical data
Promising preclinical data SCD-153 demonstrated robust hair growth in multiple AA models Week 0 Week# Week 16# (Before treatment) Vehicle thrice-a- week SCD-153 at 3% thrice-a- week n=7; 85-100% alopecia; >45 weeks age Spontaneous severe C3H/HeJ AA mouse model n=4 #n=1 from each group has completed
Slide 19: Portable to other epidermal diseases
Portable to other epidermal diseases High cross over potential to diseases with similar pathophysiology IFN induces CXCL9, CXCL10 & CXCL11 in vitiligous skin. These chemokines recruit pathogenic CD8+ T cells to the pigment-containing melanocyte in the epidermis CD8+ T cells release cytokines that de
Slide 20: SBO-154 targeting novel epitope of MUC-1
SBO-154 targeting novel epitope of MUC-1 First product from a platform leveraging the SEA domain of MUC-1 Licensed antibodies targeting MUC-1 SEA (α-β combinatorial epitope) developed at Tel-Aviv university Circulating MUC-1α in plasma and in peritumoral space blocks meaningful tumor targeting by MU
Slide 21: Hypothesis validated in multiple models
Hypothesis validated in multiple models SBO-154 causes regression of large established tumors with high MUC-1 SEA expression MUC-1 High Expression Cell Line MUC-1 Intermediate Expression Cell Line MUC-1 Low Expression Cell Line Tumor Volume (cm3) Tumor Tumor Volume (cm3) Tumor Volume (cm3) Tumor Sta
Slide 22: Preclinical programs
Preclinical programs 10+ discovery/pre-clinical programs promising pipeline enrichment Key themes driving portfolio growth 1 Novel molecular pathways in neurodegeneration 2 Antibody mediated, multi-modal tumour targeting 3 Synthetic lethality 4 Novel pathways in unaddressed autoimmune disorders SPAR
Slide 23: SPARC value proposition summary
SPARC value proposition summary 3 Clinical stage programs targeting areas of high unmet need Targeting unmet medical needs with USD20Bn+ combined peak sales potential in 6 indications Discovery & development across validated & novel biology in order to balance the risk Multi-modal portfolio; 10+ pre
Slide 24: SPARC upcoming catalysts
SPARC upcoming catalysts NSE/BSE Mumbai India - SPARC 423.35 INR Upcoming catalysts +212.40 (100.69%) past year 5 Jan, 3:21 pm IST. PROSEEK interim analysis – April 2024 1D 5D 1M 6M YTD 1Y 5Y Max PROSEEK topline – September 2024 Vodobatinib partnering 500 300 423.35 INR 5 Jan 2024 SOLARES-AD-01 inte
Slide 25: Balanced portfolio approaching value inflection
Balanced portfolio approaching value inflection The SPARC Logo is a trademarks of Sun Pharma Advanced Research Company Ltd . In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material is for use during